Abstract
Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF). They indeed have been shown to be an alternative to vitamin K antagonists (VKAs) without the burden of laboratory control. However, these new drugs compete with an effective and well-established therapy, thus bringing about a series of questions and doubts. In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with.
Publication types
-
Practice Guideline
-
Review
MeSH terms
-
Administration, Oral
-
Anticoagulants / administration & dosage*
-
Anticoagulants / adverse effects
-
Atrial Fibrillation / complications
-
Atrial Fibrillation / drug therapy*
-
Benzimidazoles / administration & dosage*
-
Benzimidazoles / adverse effects
-
Dabigatran
-
Drug Substitution
-
Evidence-Based Medicine
-
Hemorrhage / chemically induced
-
Humans
-
Italy
-
Patient Selection
-
Primary Prevention*
-
Risk Assessment
-
Risk Factors
-
Stroke / etiology
-
Stroke / prevention & control*
-
Treatment Outcome
-
Warfarin / administration & dosage*
-
Warfarin / adverse effects
-
beta-Alanine / administration & dosage
-
beta-Alanine / adverse effects
-
beta-Alanine / analogs & derivatives*
Substances
-
Anticoagulants
-
Benzimidazoles
-
beta-Alanine
-
Warfarin
-
Dabigatran